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Dietary intake and/or circulating concentrations of vitamin B6 have been associated with risk of cancer, but results are inconsistent
and mechanisms uncertain. Pyridoxal 5’-phosphate (PLP) is the most commonly used marker of B6 status. We recently proposed
the ratio 3-hydroxykynurenine/xanthurenic acid (HK/XA) as an indicator of functional vitamin B6 status, and the 4-pyridoxic acid
(PA) /(pyridoxal (PL)1PLP) ratio (PAr) as a marker of vitamin B6 catabolism during inflammation. We compared plasma PLP, HK/XA
and PAr as predictors of cancer incidence in a prospective community-based cohort in Norway. This study included 6,539 adults
without known cancer at baseline (1998–99) from the Hordaland Health Study (HUSK). HR and 95% CI were calculated for the risk of
overall and site-specific cancers using multivariate Cox proportional hazards regression with adjustment for potential confounders.
After a median follow-up time of 11.9 years, 963 cancer cases (501 men and 462 women) were identified. Multivariate-adjusted
Cox-regression showed no significant relation of plasma PLP or HK/XA with risk of incident cancer. In contrast, PAr was significantly
associated with risk of cancer with HR (95% CI)51.31 (1.12–1.52) per two standard deviation (SD) increment (p< 0.01). Further
analysis showed that PAr was a particular strong predictor of lung cancer with HR (95% CI)52.46 (1.49–4.05) per two SD increment
(p< 0.01). The present results indicate that associations of vitamin B6 with cancer may be related to increased catabolism of vitamin
B6, in particular for lung cancer where inflammation may be largely involved in carcinogenesis.
Pyridoxal-50-phosphate (PLP), pyridoxal (PL) and 4-
pyridoxic acid (PA) are the main B6 vitamers in the circula-
tion. PLP is the active form that is involved in over 140 enzy-
matic reactions including amino acid metabolism, lipid
metabolism, gluconeogenesis, one-carbon metabolism, heme
and neurotransmitter biosynthesis.1,2 PL is the transport form
that crosses cellular membranes whereas PA is a vitamin B6
catabolite excreted into the urine.3 The liver is the primary
site for vitamin B6 metabolism.3
Patients with a variety of diseases associated with inﬂam-
mation or acute phase response have consistently been
reported to have low concentrations of plasma PLP but nor-
mal erythrocyte PLP.4 These conditions include cardiovascu-
lar disease and cancer. Furthermore, plasma PLP was
inversely associated with C-reactive protein (CRP) in cohorts
of healthy subjects,4 whereas plasma PA was positively asso-
ciated with CRP and other measures of activated cellular
immunity in cardiovascular patients.5
Observational studies have suggested that dietary vitamin
B6 intake and circulating concentrations are inversely associ-
ated with risk of cancer in the colon/rectum, lung, prostate,
breast and pancreas.1,6–8 Several mechanisms have been sug-
gested, including anti-inﬂammatory effects, effects on angio-
genesis, DNA methylation, synthesis and repair and humoral
and cell-mediated immune responses.1 Randomized placebo-
controlled trials using vitamin supplements, however, have
mostly failed to decrease cancer risk.9,10
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Several steps in tryptophan catabolism via the kynurenine
pathway are vitamin B6 dependent. The ratio of two downstream
metabolites, 3-hydroxykynurenine (HK) and xanthurenic acid
(XA), i.e. the HK/XA, was recently proposed as an indicator of
functional vitamin B6 status.11
Other potentially useful substrate product ratios measured
in plasma include the established inﬂammatory marker kynu-
renine/tryptophan ratio (KTR)5 and the PA/(PL1PLP) ratio
(PAr).12 The latter is a strong indicator of inﬂammation, in
particular activated cellular immunity, indicating that
increased vitamin B6 catabolism may partly explain low PLP
concentrations in inﬂammatory conditions.4,13,14 Elevated
PAr may also reﬂect increased oxidative stress,15 which is
closely related to cancer pathogenesis.16
The aim of this study was to compare associations of dif-
ferent vitamin B6 measures, including PLP, HK/XA and PAr,
with cancer risk in a prospective, community-based cohort in
Norway.
Subjects and Methods
Study subjects
The design of the Hordaland Health Study (HUSK) has been
described in detail in previous papers17,18 and on the website:
http://husk-en.b.uib.no. The baseline survey was conducted in
1997–1999 as collaboration between the University of Bergen,
the National Institute of Public Health and the Municipal
Health Services in Hordaland, Western Norway. Men and
women born during 1925–1927 and 1950–1951 living in the
city of Bergen and its surrounding areas were invited to par-
ticipate. The present study cohort was conﬁned to 7,051 par-
ticipants recruited in the period of April 1998 to June 1999.
Information on socio-demographic variables, health status
and lifestyle factors were collected by self-administered
questionnaires.
Of the 7,051 participants, we excluded 426 participants
who were diagnosed with cancer (other than non-melanoma
skin cancer) before enrollment. Participants with missing
data on blood measurements of PLP, PL, PA, HK and XA
(n5 86) were also excluded. A total of 6,539 participants
(2,918 men and 3,621 women) were included in the ﬁnal
analysis.
The study protocol was approved by the Regional Com-
mittee for Medical and Health Research Ethics in Western
Norway (REK-Vest) and the Norwegian Data Inspectorate.
Written informed consent was obtained from all
participants.
Laboratory analyses
Non-fasting blood samples were collected at baseline. Ali-
quots of plasma were frozen at 280C until later analyses.
Plasma B6 vitamers (PLP, PL and PA), neopterin, trypto-
phan, kynurenine, HK, XA were measured by liquid
chromatography-tandem mass spectrometry (LC-MS/
MS).19,20 Serum creatinine was measured colorimetrically
using the alkaline picrate method with reagents from Roche
(Basle, Switzerland),17 before the samples were frozen. PAr
was calculated by dividing plasma PA concentrations by the
sum of plasma concentrations of PL and PLP.12 KTR was the
ratio of the concentrations of kynurenine in nmol divided by
tryptophan in mmol. Plasma high-sensitive CRP was deter-
mined by an immuno-MALDI-MS method.21 All biochemical
analyses were performed at Bevital A/S (www.bevital.no),
except for serum creatinine which was done at Ullevål Uni-
versity Hospital, Oslo. Within-day coefﬁcients of variation
(CVs) for B6 vitamers, neopterin, kynurenine and tryptophan
were 2.5–4.7% and between-day CVs were 4.8–11.1%.19
Follow-up and outcome assessment
The cohort participants were followed from the baseline sur-
vey throughout the year of 2010. Incident cancer cases were
ascertained through linkage with the Cancer Registry of Nor-
way. Cancer incidence diagnoses were coded according to the
third edition of the International Classiﬁcation of Diseases
for Oncology (ICD-O-3)22 and the 10th revision of the Inter-
national Statistical Classiﬁcation of Diseases, Injuries and
Causes of Death (ICD-10) (http://apps.who.int/classiﬁcations/
icd10/browse/2010/en). Only the ﬁrst primary neoplasm was
included in the analysis. Information on mortality was col-
lected from the Cause of Death Registry at Statistics Norway
and coded according to ICD-10.
Additional data
Smoking status was categorized as: never smokers, former
smokers, light smokers (10 cigarettes per day) and heavy
smokers (>10 cigarettes per day). Dietary data were collected
with the use of a validated self-administered food frequency
questionnaire (FFQ).23,24 The FFQ included 169 food items
and offered alternatives for frequency, number of units con-
sumed and portion sizes to capture the habitual diet informa-
tion during the past year. Intake of vegetables and fruits was
obtained from FFQ, and daily alcohol intake was calculated
using a nutrient database and software system developed at
What’s new?
Vitamin B6 status is reflected in the measure of its active form, pyridoxal 5’-phosphate (PLP). Studies disagree, however, as
to whether or not PLP measures are meaningful in relation to cancer risk, which has necessitated a search for additional
markers of vitamin B6 status. In this study, inflammation-related changes in vitamin B6 catabolism were captured effectively
by a novel marker, the 4-pyridoxic acid (PA) /(pyridoxal (PL)1 PLP) ratio (PAr). Analyses based on the detection of PAr suggest
that increased vitamin B6 metabolism and disposal are linked to increased cancer risk, particularly for lung cancer.
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the Department of Nutrition, University of Oslo.23 Following
a standard protocol, height and weight were measured in
light clothing, without shoes, to the nearest 1 cm and 0.5 kg,
respectively. Body mass index (BMI) was calculated as weight
in kilograms divided by height in meters squared (kg m22).
Statistical analysis
Statistical analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC) and R (version 2.15 for Windows, www.r-
project.org). Log-transformation was applied to plasma con-
centrations of PLP, HK/XA, PAr, neopterin, KTR and CRP to
normalize their distribution. Continuous variables are reported
as medians (interquartile ranges) and categorical variables as
numbers (percentages). Chi-square tests were used to compare
differences between incident cancer cases and non-cases for
categorical and Wilcoxon–Mann–Whitney tests for continuous
variables. Pearson correlation was calculated to examine the
relations between plasma PLP and HK/XA.
We used Cox proportional hazards models to estimate the
hazard ratios (HRs) and their 95% conﬁdence intervals (CIs)
for the risk of overall and speciﬁc cancers. Follow-up began at
baseline and ended at the date of cancer diagnosis, death, emi-
gration or December 31, 2010, whichever came ﬁrst. The pro-
portionality assumption of the models was tested and plotted
based on Schoenfeld residuals,25 and no evidence of violation
was found. Multivariate models were adjusted for gender, age
(46–49 years vs. 70–74 years), BMI (continuous), smoking
(never, former, light smokers or heavy smokers), alcohol intake
(continuous), intake of vegetables and fruits (continuous) and
creatinine (continuous). Plasma concentrations of PLP, HK/
XA and PAr were analyzed both as categorical variables (quar-
tiles) and continuous measures (per 2 SD increment after log-
transformation). Multivariable adjusted associations between
PAr and risk of overall and lung cancer were visualized by
plots using generalized additive models (GAM). To test for
potential confounding or mediation by plasma CRP, we addi-
tionally adjusted for CRP in the Cox models examining the
association of PAr with overall cancer risk. Tests for potential
interaction with smoking were performed based on ﬁrst-degree
multiplicative models.
Sensitivity analyses were performed to determine the
robustness of ﬁndings in the primary analysis by exclusion of
cases who were diagnosed during the ﬁrst 2 years of follow-
up. We further tested for the possibility of reverse causality
Table 1. Baseline characteristics of the HUSK participants
Characteristics1 Overall (n56,539)
Incident cancer
(n5963)
Non-cancer
(n55,576) p
Male (%) 2,918 (44.6) 501 (52.0) 2417 (43.4) <0.01
Age (%)
46–49 years 3,590 (54.9) 271 (28.1) 3319 (59.5) <0.01
70–74 years 2,949 (45.1) 692 (71.9) 2257 (40.5)
BMI (kg m22) 25.4 (23.1–27.9) 25.6 (23.2–28.2) 25.4 (23.1–27.8) 0.11
Smoking (%)2
Never smokers 2,576 (40.9) 320 (34.5) 2256 (42.0) <0.01
Former smokers 2,115 (33.5) 381 (41.0) 1734 (32.2)
Light smokers 882 (14.0) 134 (14.4) 748 (13.9)
Heavy smokers 733 (11.6) 94 (10.1) 639 (11.9)
Alcohol intake (g day21) 1.7 (0–6.8) 1.7 (0–6.9) 1.9 (0–6.9) 0.43
Intake of vegetables and fruits (g day21) 392 (258–566) 373 (240–544) 398 (262–574) 0.02
Creatinine (mmol l21) 79.8 (71.7–89.4) 82.0 (73.3–91.4) 79.5 (71.5–89.2) <0.01
PLP (nmol l21) 50.1 (35.8–75.1) 47.1 (32.9–75.6) 50.6 (36.2–75.0) <0.01
PL (nmol l21) 11.9 (9.1–16.6) 12.1 (9.2–18.0) 11.8 (9.0–16.5) 0.04
PA (nmol l21) 22.3 (16.7–34.5) 24.0 (17.7–38.9) 22.1 (16.5–33.7) <0.01
HK/XA ratio 2.0 (1.5–2.8) 2.2 (1.6–3.0) 2.0 (1.5–2.7) <0.01
Par 0.38 (0.29–0.51) 0.43 (0.32–0.59) 0.38 (0.29–0.50) <0.01
Neopterin (nmol l21) 7.6 (6.3–9.2) 8.2 (6.8–10.0) 7.5 (6.3–9.1) <0.01
KTR (nmol mmol21) 22.4 (18.4–27.7) 24.7 (20.2–30.1) 22.1 (18.1–27.2) <0.01
CRP (mg l21) 1.5 (0.7–3.6) 2.1 (0.9–4.2) 1.4 (0.6–3.4) <0.01
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HK/XA, 3-hydroxykynurenine/xanthurenic acid; HUSK, Hordaland Health Study; KTR,
kynurenine/tryptophan ratio; PA, 4-pyridoxic acid; PAr, 4-pyridoxic acid/(pyridoxal1 Pyridoxal 5’-phosphate) ratio; PL, pyridoxal; PLP, pyridoxal 5’-
phosphate.
1Values are given as medians (interquartile ranges) or numbers (percentages).
2Numbers of participants do not sum to the total numbers because of missing data.
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by plotting geometric mean PAr for the cancer cases by
follow-up using GAM regression adjusted for the above-
mentioned confounders. All tests were two sided and p value
<0.05 was considered statistically signiﬁcant.
Results
After a median follow-up time of 11.9 years, 963 cancer cases
(501 men and 462 women) were identiﬁed. Compared with
non-cases, incident cancer cases were more often men, older,
former or current smokers, had lower intake of vegetables and
fruits, and had higher values of all laboratory measures in
plasma/serum at baseline except PLP, which was lower in cases
than in non-cases (Table 1). Pearson correlation coefﬁcients
adjusted for age and gender showed a negative correlation
between PLP and HK/XA (Pearson r520.33, p< 0.01). The
change across increasing quartiles of PAr was due to both grad-
ually increasing concentrations of PA and decreasing concentra-
tions of PLP, but little change in PL (data not shown).
Plasma PLP was inversely associated with cancer risk (p-
trend5 0.05 after adjustment for gender and age), but this
Table 2. HRs and 95% CIs for overall cancer risk by PLP, HK/XA ratio and PAr, respectively, the Hordaland Health Study (n56,539)
Gender, age-adjusted Multivariate-adjusted
Cancer cases HR (95% CI) p trend1 HR (95% CI) p-trend1
PLP (nmol l21)
Quartile 1 293 1.00 (ref.) 0.14 1.00 (ref.) 0.10
Quartile 2 232 0.76 (0.64–0.91) 0.83 (0.68–1.00)
Quartile 3 194 0.68 (0.56–0.81) 0.69 (0.56–0.84)
Quartile 4 244 0.82 (0.69–0.98) 0.82 (0.68–0.99)
Per 2 SD increment2 0.88 (0.77–1.00) 0.05 0.90 (0.78–1.04) 0.16
HK/XA ratio
Quartile 1 190 1.00 (ref.) 0.02 1.00 (ref.) 0.04
Quartile 2 217 1.00 (0.82–1.22) 1.03 (0.83–1.28)
Quartile 3 259 1.10 (0.91–1.33) 1.09 (0.88–1.34)
Quartile 4 297 1.22 (1.01–1.47) 1.21 (0.98–1.49)
Per 2 SD increment2 1.11 (0.97–1.26) 0.14 1.06 (0.92–1.23) 0.44
Par
Quartile 1 162 1.00 (ref.) <0.01 1.00 (ref.) <0.01
Quartile 2 215 1.09 (0.88–1.33) 1.04 (0.83–1.31)
Quartile 3 262 1.19 (0.97–1.46) 1.22 (0.98–1.52)
Quartile 4 324 1.34 (1.10–1.64) 1.29 (1.04–1.61)
Per 2 SD increment2 1.31 (1.15–1.50) <0.01 1.31 (1.12–1.52) <0.01
Abbreviations: HK/XA, 3-hydroxykynurenine/xanthurenic acid; PAr, 4-pyridoxic acid/(pyridoxal1 Pyridoxal 5’-phosphate) ratio; PLP, pyridoxal 5’-
phosphate.
Multivariate-adjusted models: adjusted for gender, age (46–49 years vs. 70–74 years), BMI (continuous), smoking (never, former, light smokers or
heavy smokers), alcohol intake (continuous), intake of vegetables and fruits (continuous) and creatinine (continuous).
1Tests for a linear trend across quartiles were performed by modelling quartile-specific median values as a continuous variable.
2HRs (95% CIs) are reported per 2 standard deviation (SD) increment in log-transformed data. The SD for ln PAr was 0.45, therefore 2 SD increment
in log PAr corresponds to approximately 2.4 times of PAr ratio.
Table 3. Adjusted HRs and 95% CIs for the risk of main specific cancer types in relation to plasma PAr1
HR (95% CI) per 2SD increment
Cancer type Number of cases Model 12 p Model 23 p
Colorectal cancer 158 1.45 (1.02–2.06) 0.04 1.45 (1.00–2.08) 0.05
Prostate cancer 129 1.00 (0.65–1.52) 0.98 0.90 (0.58–1.39) 0.63
Breast cancer 98 1.03 (0.65–1.61) 0.91 1.00 (0.63–1.60) 0.99
Lung cancer 85 2.46 (1.49–4.05) <0.01 2.37 (1.43–3.92) <0.01
Abbreviations: PAr, 4-pyridoxic acid/(pyridoxal1 Pyridoxal 5’-phosphate) ratio.
1Plamsa PAr were log-transformed
2Adjusted for gender, age (46–49 years vs. 70–74 years), BMI (continuous), smoking (never, former, light smokers or heavy smokers), alcohol intake
(continuous), intake of vegetables and fruits (continuous) and creatinine (continuous)
3Additionally adjusted for CRP (continuous).
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association was not statistically signiﬁcant after multiple
adjustment. HR for HK/XA comparing highest vs. lowest quar-
tiles was 1.22 (95% CI: 1.01–1.47) in a model adjusted for age
and gender, but the estimate and also HR per 2SD were attenu-
ated after multivariate adjustment (Table 2). Plasma PAr was
associated with a signiﬁcantly elevated risk of incident cancer
(Table 2). After adjustment for gender, age, BMI, smoking,
alcohol intake, intake of vegetables and fruits and creatinine,
the HR for the highest vs. lowest quartile was 1.29 (95% CI:
1.04–1.61; p-trend< 0.01). Analysis of PAr as a continuous
variable showed similar results (HR (95% CI)5 1.31 (1.12–
1.52) per 2 SD increment). Also, we conducted a secondary
analysis on PAr and overall cancer risk by additional adjust-
ment for plasma CRP in the Cox models and observed slightly
attenuated but signiﬁcant results (data not shown).
Associations between PAr and the risk of main speciﬁc
cancer types are shown in Table 3. The strongest association
was found for lung cancer (n5 85) (HR (95% CI)5 2.46
(1.49–4.05) per 2 SD increment). Within the lung cancer
group, we compared risk associations of PAr with PLP, HK/
XA and the inﬂammatory markers (CRP, neopterin and KTR).
Neither PLP nor HK/XA was signiﬁcantly associated with lung
cancer (data not shown), but a positive association was found
for CRP (HR (95% CI)5 2.06 (1.20–3.53) per 2 SD incre-
ment). Similar to the analysis on overall cancer risk, analysis
on PAr and lung cancer risk by additional adjustment for
plasma CRP in the Cox models yielded slightly attenuated but
still signiﬁcant results. The positive dose-response relations of
plasma PAr with risk of overall cancer and lung cancer are
shown in Figure 1, demonstrating close to linear associations
through the whole distribution of PAr on a logarithmic scale.
Sensitivity analyses in which the ﬁrst 2 years of follow-up
were excluded showed essentially no change in risk estimates
(data not shown). In addition, analysis by generalized addi-
tive models showed that the concentration of PAr was not
associated with time from baseline to diagnosis (follow up) in
cancer patients (Fig. 2).
No statistically signiﬁcant interaction was observed
between PAr and smoking status for risk of overall cancer (p
interaction5 0.82) and lung cancer (p interaction5 0.14).
Discussion
Principal findings
In this community-based cohort study, we observed that high
plasma PA/(PL1PLP) ratio (PAr) was associated with an
increased risk of incident cancer. By comparison, the active B6
vitamer PLP and our recently proposed indicator of functional
vitamin B6 status, HK/XA, were not signiﬁcantly associated with
overall cancer risk after multiple adjustment. The association of
PAr with cancer risk was particularly strong for lung cancer.
Associations of PLP and HK/XA with cancer risk
HK/XA was negatively associated with PLP, and the magnitude
of the correlation was similar to that previously reported.11
Figure 1. Dose–response relationships of plasma PAr with risk of overall cancer and lung cancer by generalized additive regression. Models
were adjusted for gender, age (46–49 years vs. 70–74 years), BMI (continuous), smoking (never, former, light smokers or heavy smokers),
alcohol intake (continuous), intake of vegetables and fruits (continuous) and creatinine (continuous). The black solid lines show HRs and
the shaded areas show 95% CIs. Density plots show the distribution of PAr (log scale), and vertical lines denote the 5th, 50th, and 95th
percentiles. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Plasma PLP demonstrated a borderline negative association
with cancer risk after adjustment for gender and age, which is
essentially consistent with previous ﬁndings.1,6 After multiple
adjustment, this association, and also the positive association
of the functional vitamin B6 status, HK/XA, with cancer risk,
were no longer signiﬁcant. This demonstrates agreement
between the two indicators of vitamin B6 status, but also that
associations of vitamin B6 with cancer are explained through
other confounding variables in the study cohort.
Possible mechanisms for the association between PAr and
cancer risk
It is now well established that chronic inﬂammation is cau-
sally related to cancer development.26–28 Recent epidemiologi-
cal and experimental work has shown that chronic
inﬂammatory processes contribute to several steps of tumori-
genesis.28 Mechanisms involved in cancer-related inﬂamma-
tion may include genotoxicity/genetic instability, aberrant
tissue repair, proliferative responses, invasion and metastasis,
and subversion of adaptive immunity.16,27 Chronic inﬂamma-
tion is capable of inducing oxidative and nitrosative stress,
which leads to DNA mutations in cells.29
Previous evidence has shown lower plasma concentrations
of PLP during inﬂammation and in inﬂammatory dis-
eases.4,13,14 The inverse association may reﬂect altered distri-
bution of PLP from circulation to tissues affected by, or
otherwise involved in inﬂammation.5,14 Suggested mechanisms
include an increased recruitment of PLP cofactor for enzymes
of the kynurenine pathway of tryptophan degradation, synthe-
sis and catabolism of the immunomodulatory sphingolipids,
ceramide and sphingosine 1-phosphate, and for serine
hydroxymethylase to support immune cell proliferation.4,13
Consequently, it is possible that the previously reported asso-
ciation of low plasma PLP and cancer risk1,6–8 is related to
these processes. We recently suggested that increased vitamin
B6 catabolism during inﬂammation may be an additional
cause of low plasma PLP.12 Inﬂammation is accompanied by
oxidative and aldehyde stress.29 In response, several enzymes,
including aldehyde oxidase and aldehyde hydrogenase in liver
and/or extrahepatic tissues are upregulated and may be
involved in the spurious oxidation of PL to PA, leading to an
increase in PAr.12 In addition, PAr may capture altered vita-
min B6 distribution during the inﬂammatory process.
PAr by cancer sites
We found a particularly strong association between PAr and
the risk of lung cancer, whereas the associations with non-lung
cancer sites were weak. This is consistent with previous obser-
vations showing that lung cancer is associated with a greater
activation of systemic inﬂammation than other cancer types.30
Notably, the activity of aldehyde dehydrogenase, one of the
two enzymes catalyzing PL,31 was found to be associated with
lung adenocarcinoma stem cells.32 Among the other cancer
sites examined, PAr was a stronger risk marker for colorectal
than for prostate and breast cancer, reﬂecting again the degree
of inﬂammatory involvement for these cancer types.30
Causation and interaction with smoking
Reverse causation in the context of the present study means
that the carcinogenic process may affect the plasma PAr
level. If this was the case one would expect a stronger associ-
ation of PAr with cancer risk, and higher PAr levels for those
with a short time interval between PAr measurement and
cancer diagnosis. However, two observations do not support
this: First, sensitivity analyses by excluding the ﬁrst 2 years of
follow-up did essentially not affect the risk estimates. Second,
the GAM plot showed no association of PAr with time from
PAr measurement to cancer diagnosis.
The association between cancer risk and PAr could be
explained by an increase in PAr caused by factors involved in
carcinogenesis, such as inﬂammation and related processes
including infection, smoking and environmental irritants.28 In
other words, inﬂammation may be the underlying cause of can-
cer whereas circulating PLP and PAr are only inﬂammatory
Figure 2. Plasma PAr level versus follow-up time among partici-
pants with incident cancer by generalized additive regression. Mod-
els were adjusted for age, gender, BMI, smoking, alcohol intake,
intake of vegetables and fruits and creatinine. The solid lines show
geometric mean of PAr and the shaded area shows 95% CIs for
the slope of the PAr-association. Density plot shows the distribu-
tion of time to cancer incidence, and vertical lines denote the 5th,
50th and 95th percentiles. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
E
pi
de
m
io
lo
gy
6 Vitamin B6 markers and cancer risk
Int. J. Cancer: 00, 00–00 (2014) VC 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
indicators, and have no direct role in the development of cancer.
This explains why B-vitamin supplements have failed to
decrease cancer risk in the randomized placebo-controlled tri-
als,9,10 and support the idea of PAr as a marker of increased vita-
min B6 catabolism during inﬂammation and immune
activation.12
In addition, smoking is the leading risk factor for lung
cancer and is associated with elevated concentrations of
inﬂammatory markers.33 However, the association of PAr
with lung cancer risk was similar across smoking categories.
This shows that PAr and smoking are essentially mutually
independent risk predictors, and suggests that PAr is an indi-
cator of other aspects of the inﬂammatory response than
those elicited by smoking. In support of these arguments we
previously reported a weak association between PAr and
smoking.12
Strengths and limitations
Strengths mainly lie in the prospective design, and long and
complete follow-up. Our study included a comprehensive
panel of vitamin B6 markers and their relation to cancer risk.
However, the study has some limitations. First, the ﬁndings
are based on a relatively small number of cases, especially
when analyzing risk for speciﬁc cancer types. The results
should therefore be veriﬁed in larger cohorts. Second, a rela-
tively small proportion (3.2%) of our study population had
vitamin B6 deﬁciency deﬁned as plasma PLP< 20 nmol
L21.34 Thus, studies in other populations with a larger vari-
ability in vitamin B6 status are needed for generalizability.
Third, our results could also be affected by other dietary fac-
tors, although intake of vegetables and fruits were considered.
However, PAr was, unlike PL, PA and PLP, not related to
intake of dietary supplements.12
Conclusions
While we found little evidence to support vitamin B6 sta-
tus as an independent predictor of incident cancer, we are,
to the best of our knowledge, the ﬁrst to present evidence
that increased metabolism and disposal of vitamin B6, as
captured by plasma PAr, is associated with increased can-
cer risk. Because of the limited number of speciﬁc cancer
types, future studies that include a larger number of cases
are warranted to conﬁrm these ﬁndings, and to further
elucidate the role of vitamin B6 catabolism in
carcinogenesis.
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